Artificial Intelligence–Based Model Exploiting Hematoxylin and Eosin Images to Predict Rare Gene Mutations in Patients With Lung Adenocarcinoma
JCO Clinical Cancer Informatics · 2025
DOI: 10.1200/cci-25-00093 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2025. Verfasst von Peiling Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, the First Affiliated Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Mutation, Artificial Intelligence, Lung Neoplasms. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Accurately identifying gene mutations in lung cancer is crucial for treatment, while molecular diagnostic methods are time-consuming and complex. This study aims to develop an advanced deep learning model to address this issue. METHODS In this study, the ResNeXt101 model framework was established to predict the gene mutation status in lung adenocarcinoma. The model was trained and validated using data from two cohorts: cohort 1, comprising 144 patients from the First Affiliated Hospital of China Medical University, and cohort 2, which includes 69 patients from the The Cancer Genome Atlas-Lung Adenocarcinoma public database. The model was trained and validated on the two data sets, respectively, and they served as external test sets for each other to further verify the performance of the model. Additionally, we tested the trained model on a metastatic cancer data set, which included metastases to organs outside the lungs. The performance of the model was evaluated using the AUC, accuracy, precision, recall, and F1 score. RESULTS In cohort 1, the model achieved an AUC ranging from 0.93 to 1. In the external test on cohort 2, it performed well in predicting five of the six genes (AUC = 0.85-1). When tested on the metastatic cancer data set, it successfully predicted mutations of three of the six genes (AUC = 0.72-0.80). CONCLUSION The artificial intelligence model developed in this study has a high accuracy in predicting gene mutations in lung adenocarcinoma, which is conducive to improving the management of patients with lung adenocarcinoma and promoting precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, the First Affiliated Hospital of China Medical University, Shenyang, China.
- College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, China.
- Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang, China.
- Department of Pathology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
ORCID-Profile: Weixing Chen, Yini Alatan, Yuan Miao
Zitieren
APA
Yu, P., Chen, W., Liu, N., Yu, Y., Guo, H., Yuan, Y., Guo, W., Alatan, Y., Zhao, J., Su, H., Nie, S., Cui, X., & Miao, Y. (2025). Artificial Intelligence–Based Model Exploiting Hematoxylin and Eosin Images to Predict Rare Gene Mutations in Patients With Lung Adenocarcinoma. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci-25-00093
Vancouver
Yu P, Chen W, Liu N, Yu Y, Guo H, Yuan Y, et al. Artificial Intelligence–Based Model Exploiting Hematoxylin and Eosin Images to Predict Rare Gene Mutations in Patients With Lung Adenocarcinoma. JCO Clinical Cancer Informatics. 2025. doi:10.1200/cci-25-00093
BibTeX
@article{Yu2025,
author = {Yu, Peiling and Chen, Weixing and Liu, Nan and Yu, Yang and Guo, Hongyu and Yuan, Yinan and Guo, Weilin and Alatan, Yini and Zhao, Jinming and Su, Hongbo and Nie, Siru and Cui, Xiaoyu and Miao, Yuan},
title = {Artificial Intelligence–Based Model Exploiting Hematoxylin and Eosin Images to Predict Rare Gene Mutations in Patients With Lung Adenocarcinoma},
journal = {JCO Clinical Cancer Informatics},
year = {2025},
doi = {10.1200/cci-25-00093}
}
EUVIMED